You need to enable JavaScript to run this app.
Recon: Roche Nabs Priority Review for Tecentriq in NSCLC; FDA Rejects 6-Week Dosing Schedule for Keytruda
Recon
Michael Mezher
ReconMichael Mezher
ReconMichael Mezher